Precision for Medicine
Nicholas Richardson, DO, MPHVice President
Nicholas Richardson, DO, MPH, is Vice President of Clinical Development at Precision for Medicine and former FDA Deputy Director of the Division of Hematologic Malignancies 2. At the FDA, Dr. Richardson led regulatory oversight for development of therapies for hematologic malignancies including lymphoma, chronic lymphocytic leukemia , and multiple myeloma (MM). Dr. Richardson also spearheaded initiatives to develop novel endpoints in blood cancer, such as minimal residual disease (MRD) in MM and chronic lymphocytic leukemia, helping accelerate drug development.
Insights from Nicholas Richardson, DO, MPH
Research & Development | White Paper
The ADC Pendulum: Understanding ADC Withdrawals to build better therapies
Research & Development | White Paper
Advancing Radiopharmaceuticals From Regulatory Approval to Global Access
Research & Development | White Paper
Navigating Global Regulations for Radiopharmaceutical Development